195 related articles for article (PubMed ID: 8246811)
1. Studies on mutational cross-resistance between ciprofloxacin, novobiocin and coumermycin in Escherichia coli and Staphylococcus warneri.
Howard BM; Pinney RJ; Smith JT
Microbios; 1993; 75(304):185-95. PubMed ID: 8246811
[TBL] [Abstract][Full Text] [Related]
2. Antagonism between bactericidal activities of 4-quinolones and coumarins gives insight into 4-quinolone killing mechanisms.
Howard BM; Pinney RJ; Smith JT
Microbios; 1994; 77(311):121-31. PubMed ID: 8152392
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
Zhao X; Quinn B; Kerns R; Drlica K
J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
[TBL] [Abstract][Full Text] [Related]
4. 4-Quinolone interactions with gyrase subunit B inhibitors.
Lewin CS; Howard BM; Smith JT
J Med Microbiol; 1991 Dec; 35(6):358-62. PubMed ID: 1661337
[TBL] [Abstract][Full Text] [Related]
5. In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid.
Cattoir V; Lesprit P; Lascols C; Denamur E; Legrand P; Soussy CJ; Cambau E
J Antimicrob Chemother; 2006 Nov; 58(5):1054-7. PubMed ID: 16984897
[TBL] [Abstract][Full Text] [Related]
6. [Mutations of gyrA in ciprofloxacin resistant Escherichia coli strains].
Eraç B; Gill A; Amyes SG; Gülay Z
Mikrobiyol Bul; 2003; 37(2-3):125-30. PubMed ID: 14593893
[TBL] [Abstract][Full Text] [Related]
7. cysB and cysE mutants of Escherichia coli K12 show increased resistance to novobiocin.
Rakonjac J; Milic M; Savic DJ
Mol Gen Genet; 1991 Aug; 228(1-2):307-11. PubMed ID: 1886615
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin.
Gombert ME; Aulicino TM
Antimicrob Agents Chemother; 1984 Dec; 26(6):933-4. PubMed ID: 6570085
[TBL] [Abstract][Full Text] [Related]
9. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
Pasquali F; Manfreda G
Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination.
Perronne CM; Malinverni R; Glauser MP
Antimicrob Agents Chemother; 1987 Apr; 31(4):539-43. PubMed ID: 3606060
[TBL] [Abstract][Full Text] [Related]
11. Effects of novobiocin, coumermycin A1, clorobiocin, and their analogs on Escherichia coli DNA gyrase and bacterial growth.
Hooper DC; Wolfson JS; McHugh GL; Winters MB; Swartz MN
Antimicrob Agents Chemother; 1982 Oct; 22(4):662-71. PubMed ID: 6295263
[TBL] [Abstract][Full Text] [Related]
12. Brachyspira (Serpulina) hyodysenteriae gyrB mutants and interstrain transfer of coumermycin A(1) resistance.
Stanton TB; Matson EG; Humphrey SB
Appl Environ Microbiol; 2001 May; 67(5):2037-43. PubMed ID: 11319078
[TBL] [Abstract][Full Text] [Related]
13. nov: a new genetic locus that affects the response of Escherichia coli K-12 to novobiocin.
Rakonjac J; Milic M; Ajdic-Predic D; Santos D; Ivanisevic R; Savic DJ
Mol Microbiol; 1992 Jun; 6(11):1547-53. PubMed ID: 1625583
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
[TBL] [Abstract][Full Text] [Related]
15. Curing of plasmid pE194 with novobiocin and coumermycin A1 in Bacillus subtilis and Staphylococcus aureus.
Gadó I; Tóth I; Szvoboda G
Zentralbl Bakteriol Mikrobiol Hyg A; 1987 Jun; 265(1-2):136-45. PubMed ID: 2823505
[TBL] [Abstract][Full Text] [Related]
16. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of DNA gyrase inhibitors, singly and in combination, against Mycobacterium avium complex.
Babinchak TJ; Fass RJ
Diagn Microbiol Infect Dis; 1992; 15(4):367-70. PubMed ID: 1319302
[TBL] [Abstract][Full Text] [Related]
18. Genetic analysis of the biosynthesis of the pyrrole and carbamoyl moieties of coumermycin A1 and novobiocin.
Xu H; Wang ZX; Schmidt J; Heide L; Li SM
Mol Genet Genomics; 2002 Nov; 268(3):387-96. PubMed ID: 12436260
[TBL] [Abstract][Full Text] [Related]
19. Emergence and maintenance of resistance to fluoroquinolones and coumarins in Staphylococcus aureus: predictions from in vitro studies.
Vickers AA; O'Neill AJ; Chopra I
J Antimicrob Chemother; 2007 Aug; 60(2):269-73. PubMed ID: 17556355
[TBL] [Abstract][Full Text] [Related]
20. Dose-related selection of fluoroquinolone-resistant Escherichia coli.
Olofsson SK; Marcusson LL; Strömbäck A; Hughes D; Cars O
J Antimicrob Chemother; 2007 Oct; 60(4):795-801. PubMed ID: 17635875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
